Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CSLLY Relative to the S&P 500

CSLLY Relative to the Sector

Seasonal Chart Analysis

Analysis of the CSL Limited (OTCMKT:CSLLY) seasonal charts above shows that a Buy Date of January 16 and a Sell Date of May 6 has resulted in a geometric average return of 4% above the benchmark rate of the S&P 500 Total Return Index over the past 16 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 16 years by an average of 3.24% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

To download CSLLY seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CSLLY